{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.75","upperLimit":"3.98","value":"3.86"},{"groupId":"OG001","lowerLimit":"4.48","upperLimit":"4.48","value":"4.48"},{"groupId":"OG002","lowerLimit":"4.5","upperLimit":"5.14","value":"5.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"1-5 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.12","upperLimit":"3.6","value":"3.46"},{"groupId":"OG001","lowerLimit":"3.32","upperLimit":"4.59","value":"3.64"},{"groupId":"OG002","lowerLimit":"3.2","upperLimit":"4.44","value":"3.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"6-11 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.76","upperLimit":"5.4","value":"4.88"},{"groupId":"OG001","lowerLimit":"4.07","upperLimit":"5.07","value":"4.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"12-17 years"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"18+ years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"Cmax is defined as maximum plasma concentration of ibrutinib. As per planned analyses, pharmacokinetic (PK) parameters for Part 1 were presented per dose group (240 mg/m\\^2, 329 mg/m\\^2 and 440 mg/m\\^2) and age group (1-5, 6-11, 12-17 and \\>18 years). As planned in protocol, the PK parameters were presented per dose group as dosing was dependent on age.","dispersionType":"Full Range","groups":[{"description":"Participants received 240 milligrams per meter square (mg/m\\^2) ibrutinib based on age group for 3 treatment cycles with each cycle of 21 or 28 days long in part 1.","id":"OG000","title":"Part 1: Ibrutinib: 240 mg/m^2"},{"description":"Participants received 329 mg/m\\^2 ibrutinib based on age group for 3 treatment cycles with each cycle of 21 or 28 days long in part 1.","id":"OG001","title":"Part 1: Ibrutinib: 329 mg/m^2"},{"description":"Participants received 440 mg/m\\^2 ibrutinib based on age group for 3 treatment cycles with each cycle of 21 or 28 days long in part 1.","id":"OG002","title":"Part 1: Ibrutinib: 440 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"PK analysis set included participants in the ibrutinib group that received ibrutinib doses and had quantifiable plasma concentration of ibrutinib. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. Here, \"n (number analyzed)\" is defined as number of participants analyzed for specified category.","reportingStatus":"POSTED","timeFrame":"Up to Cycle 3 (each cycle of 21 or 28 days)","title":"Part 1: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib","type":"PRIMARY","unitOfMeasure":"nanograms per milliliter (ng/mL)"}